TD Cowen analyst Tyler Van Buren has reiterated their bullish stance on IMNM stock, giving a Buy rating yesterday.
Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Immunome’s promising developments. The company is advancing varegacestat, a gamma secretase inhibitor, through Phase III trials for desmoid tumors, with expectations of competitive efficacy based on Phase II results. Immunome’s strategic acquisition of varegacestat from Ayala, coupled with the potential for significant market value if successful, underpins the positive outlook.
Additionally, Immunome is expanding its antibody-drug conjugate (ADC) pipeline, which adds to its growth potential. The strong Phase II data, showcasing a high overall response rate and promising dose-dependent results, bolster confidence in the upcoming Phase III outcomes. The anticipated topline data in the second half of 2025, along with ongoing manufacturing and pharmacology efforts, further support the Buy rating as the company positions itself for an eventual NDA filing.
According to TipRanks, Van Buren is an analyst with an average return of -2.6% and a 39.29% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, BridgeBio Pharma, and Arcutis Biotherapeutics.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $20.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com